UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 462

Sortiert nach

The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector

Cancer discovery, 2019-10, Vol.9 (10), p.1422-1437

2019

Volltextzugriff (PDF)

Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo -Expanded Autologous NK Cells

Clinical cancer research, 2018-08, Vol.24 (16), p.4006-4017

2018

Volltextzugriff (PDF)

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

Blood, 2017-06, Vol.129 (25), p.3294-3303

2017

Volltextzugriff (PDF)

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

Cancer Immunology, Immunotherapy, 2013-12, Vol.62 (12), p.1841-1849

2013

Volltextzugriff (PDF)

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma

Clinical cancer research, 2015-09, Vol.21 (18), p.4055-4061

2015

Volltextzugriff (PDF)

The IL-15-AKT-XBP1s signaling pathway contributes to effector functions and survival in human NK cells

Nature immunology, 2019-01, Vol.20 (1), p.10

2019

Volltextzugriff (PDF)

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

Blood, 2011-12, Vol.118 (24), p.6387-6391

2011

Volltextzugriff (PDF)

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

Blood, 2012-11, Vol.120 (22), p.4324-4333

2012

Volltextzugriff (PDF)

Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells

Blood, 2009-09, Vol.114 (13), p.2667-2677

2009

Volltextzugriff (PDF)

Checkpoint inhibition in myeloma

Hematology, 2016-12, Vol.2016 (1), p.528-533

Benson, Jr, Don M

2016

Volltextzugriff (PDF)

The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity

Molecular cancer, 2010-06, Vol.9 (1), p.165-165, Article 165

2010

Volltextzugriff (PDF)

The role of natural killer cells in immunity against multiple myeloma

Leukemia & lymphoma, 2012-09, Vol.53 (9), p.1666-1676

2012

Volltextzugriff (PDF)

A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells

International journal of cancer, 2012-03, Vol.130 (6), p.1459-1469

2012

Volltextzugriff (PDF)

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

Blood, 2014-05, Vol.123 (22), p.3390-3397

2014

Volltextzugriff (PDF)

A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma

Cancer immunology research, 2018-07, Vol.6 (7), p.776-787

2018

Volltextzugriff (PDF)

Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma

Journal of clinical oncology, 2012-06, Vol.30 (16), p.1960-1965

2012

Volltextzugriff (PDF)

The Transcription Factor AHR Prevents the Differentiation of a Stage 3 Innate Lymphoid Cell Subset to Natural Killer Cells

Cell reports (Cambridge), 2014-07, Vol.8 (1), p.150-162

2014

Volltextzugriff (PDF)

Survival outcomes following autologous stem cell transplant with melphalan 140mg/m2 versus 200mg/m2 preparative regimens in patients with multiple myeloma

Leukemia & lymphoma, 2023-07, Vol.ahead-of-print (ahead-of-print), p.1-7

2023

Volltextzugriff (PDF)

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

Blood, 2014-05, Vol.123 (22), p.3398-3405

2014

Volltextzugriff (PDF)

Ninety-minute daratumumab infusion is safe in multiple myeloma

Leukemia, 2018-11, Vol.32 (11), p.2495-2518

2018

Volltextzugriff (PDF)

Retraction Notice to: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development

Cancer cell, 2022-11, Vol.40 (11), p.1442-1442

2022

Volltextzugriff (PDF)

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

Blood, 2012-11, Vol.120 (22), p.4317-4323

2012

Volltextzugriff (PDF)

Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers

Journal of proteomics, 2016-03, Vol.136, p.89-98

2016

Volltextzugriff (PDF)

Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function

JCI insight, 2021-03, Vol.6 (6)

2021

Volltextzugriff (PDF)

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

Blood, 2014-05, Vol.123 (22), p.3406-3413

2014

Volltextzugriff (PDF)

1 – 25 von 462

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(356)
Mit Volltextzugriff
(382)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(462)
Japanisch
(28)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector

Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo -Expanded Autologous NK Cells

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma

The IL-15-AKT-XBP1s signaling pathway contributes to effector functions and survival in human NK cells

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells

Checkpoint inhibition in myeloma

The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity

The role of natural killer cells in immunity against multiple myeloma

A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma

Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma

The Transcription Factor AHR Prevents the Differentiation of a Stage 3 Innate Lymphoid Cell Subset to Natural Killer Cells

Survival outcomes following autologous stem cell transplant with melphalan 140mg/m2 versus 200mg/m2 preparative regimens in patients with multiple myeloma

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

Ninety-minute daratumumab infusion is safe in multiple myeloma

Retraction Notice to: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers

Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

Suchergebnisse filtern